Florida Cancer Specialists & Research Institute Leverages Real-World Evidence Capabilities To Advance Blood Cancer Treatment
Txylo.com/10286417
Trending...
- RemoteIoT - Revolutionises Remote Device Management With Secure, Easy-to-Use Web-Based SSH Access
- Governor Abbott Signs Largest Generational Water Investment In Texas History In Lubbock
- Pregis Shares 2024 Sustainability Report Highlighting Progress in Circular Product Innovation, Emissions Accountability, and Global Impact
FORT MYERS, Fla., Sept. 6, 2024 ~ At the Society for Hematologic Oncology's 2024 annual meeting in Houston this week, real-world evidence research from Florida Cancer Specialists & Research Institute (FCS) is being presented. FCS President and Managing Physician, Dr. Lucio N. Gordan, spoke about the institute's investments in developing unique datasets that have led to significant insights and improved patient outcomes globally.
Earlier this year, FCS launched a formal effort to collect real-world data from over one million patients and combine it with advanced data science techniques to generate insights that can enhance patient care and aid in the discovery of new therapies. The FCS Real-World Evidence team works with both internal and external partners to provide valuable insights for improving treatment decisions and clinical outcomes based on real-world data.
Dr. Gustavo Fonseca, a medical oncologist and hematologist at FCS, expressed excitement about the institute's contributions to the understanding and treatment of blood cancers and related diseases. He believes that their robust clinical expertise and informatics capabilities make them well-equipped to make significant contributions in this field.
More on Txylo.com
Amanda Warner, FCS director of real-world evidence, will be presenting a poster titled "Perspectives of single-center community hematologists/oncologists on minimal residual disease testing among patients with multiple myeloma." The research was conducted in partnership with Janssen Scientific Affairs, LLC and co-authored by Dr. Gordan, Trevor Heritage (FCS senior vice president and data officer), Amy Ming (FCS senior director of informatics), and Ernest Griffin (FCS manager of data science).
Another poster abstract presentation will feature research results co-authored by Dr. Gordan, Dr. Fonseca, Trevor Heritage, Amanda Warner, Amy Ming, and Ernest Griffin. The study focuses on the management of patients with lower-risk myelodysplastic syndromes in a large US community oncology practice.
The Society for Hematologic Oncology (SOHO) is the only worldwide society dedicated to hematologic malignancies. The 2024 annual meeting will feature presentations from internationally recognized experts on various topics related to leukemias, lymphomas, myeloma, myelodysplastic neoplasms, myeloproliferative neoplasms, and cellular therapy developments.
FCS's participation in this prestigious event highlights their commitment to advancing the understanding and treatment of blood cancers and related diseases. With their extensive informatics capabilities and real-world evidence research, FCS is making significant contributions to improving patient outcomes and enhancing the discovery of new therapies.
Earlier this year, FCS launched a formal effort to collect real-world data from over one million patients and combine it with advanced data science techniques to generate insights that can enhance patient care and aid in the discovery of new therapies. The FCS Real-World Evidence team works with both internal and external partners to provide valuable insights for improving treatment decisions and clinical outcomes based on real-world data.
Dr. Gustavo Fonseca, a medical oncologist and hematologist at FCS, expressed excitement about the institute's contributions to the understanding and treatment of blood cancers and related diseases. He believes that their robust clinical expertise and informatics capabilities make them well-equipped to make significant contributions in this field.
More on Txylo.com
- Lottery.com Inc. Secures $300 Million in Growth Capital, Confirms Nasdaq Compliance & Acquires UAE Sports Incubator Amid High-Profile Brand Exposure
- $750 Million Ketamine Drug Market Withing Reach via New Commissioner's National Priority Vouchers with Anticipated Approval by Year-End for NRx
- NUFABRX awarded Therapeutic Compression agreement with Premier, Inc
- Luxurious Estate in Keenes Pointe Hits the Market at $2.9 Million
- Simplilearn Partners with Michigan Engineering Professional Education to Launch Generative AI Applications for Leaders Program
Amanda Warner, FCS director of real-world evidence, will be presenting a poster titled "Perspectives of single-center community hematologists/oncologists on minimal residual disease testing among patients with multiple myeloma." The research was conducted in partnership with Janssen Scientific Affairs, LLC and co-authored by Dr. Gordan, Trevor Heritage (FCS senior vice president and data officer), Amy Ming (FCS senior director of informatics), and Ernest Griffin (FCS manager of data science).
Another poster abstract presentation will feature research results co-authored by Dr. Gordan, Dr. Fonseca, Trevor Heritage, Amanda Warner, Amy Ming, and Ernest Griffin. The study focuses on the management of patients with lower-risk myelodysplastic syndromes in a large US community oncology practice.
The Society for Hematologic Oncology (SOHO) is the only worldwide society dedicated to hematologic malignancies. The 2024 annual meeting will feature presentations from internationally recognized experts on various topics related to leukemias, lymphomas, myeloma, myelodysplastic neoplasms, myeloproliferative neoplasms, and cellular therapy developments.
FCS's participation in this prestigious event highlights their commitment to advancing the understanding and treatment of blood cancers and related diseases. With their extensive informatics capabilities and real-world evidence research, FCS is making significant contributions to improving patient outcomes and enhancing the discovery of new therapies.
Filed Under: Business
0 Comments
Latest on Txylo.com
- Elevated Healing Treatment Centers: Redefining Mental Health Care with Compassionate, Evidence-Based, and Accessible Services
- SnapRefund and Centinel Announce Partnership to Launch PowerProtect™ Membership Program
- Texas: Governor Abbott Appoints Hussenoeder To TexNet Technical Advisory Committee
- Texas: Governor Abbott Appoints Young To 62nd Judicial District Court
- Texas: Governor Abbott Vetoes Senate Bill 3 (89R)
- Carlonoscopen Launches Base-Zero Number System — A New Mathematical Language for Tomorrow's Tech
- Flotek Announces Second Quarter 2025 Earnings Release and Conference Call Schedule
- New Study Reveals Nearly Half Of TikTok Shop Stores Generate Zero Sales Despite Platform's $100 Million Black Friday Success
- Speranza Dental Implant Centers Opens Their First Location
- Stalking Butler to revolutionize the trading industry
- WWSG Announces Exclusive Speaking Partnership with Former Australian Prime Minister Tony Abbott
- Judge Kimberly Allen Announces Campaign for 69th Judicial District Court in 2026 Republican Primary
- Aidaptive and BizCor Expand Inhabit Partnership with Native Enterprise-Grade Search for Streamline Customers
- Pikmykid Partners with Vivi to Enhance School Emergency Communication and Safety
- AI Meets Cybersecurity: IQSTEL and Cycurion Take Aim at $500 Billion Market Opportunity
- N A S D A Q Compliance Achieved Following Active Trading and Financing, UAE Acquisition & Major Brand Events: Lottery.com Inc., (N A S D A Q: LTRY)
- Caterpillar Inc. to Host 2025 Investor Day Nov. 4
- New Frontier Aerospace Successfully Tests Its Revolutionary Mjölnir Rocket Engine
- Profiting from Elder Harm: The Push to End Psychiatric Drugging in Nursing Homes
- Summit Welcomes David Beck, CPA, QPA, ERPA, as Senior ERISA Consultant